Anti-programmed cell death (PD)-1/PD-ligand 1 (L1) therapies have significantly improved the outcomes for non-small cell lung cancer (NSCLC) patients in recent years. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.